GlassScriptPhysician profile
Ulysses C Walls
NPI 1932101789
$20,345.53
in general payments reported to CMS, 2019-2025
24 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,433 · 2021: $1,536 · 2022: $1,520 · 2023: $1,339 · 2024: $1,519 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,641 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,641.28 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,772.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,428.32 | 2019-2025 | Farxiga, Breztri, Brilinta |
| Novartis Pharmaceuticals Corporation | $1,726.55 | 2019-2025 | Leqvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,526.08 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $1,109.79 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $907.73 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $516.47 | 2019-2022 | |
| Amgen INC. | $491.94 | 2019-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $475.23 | 2021-2025 | |
| Esperion Therapeutics, INC. | $305.71 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $268.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.21 | 2023-2025 | Lifevest |
| Scpharmaceuticals INC. | $145.42 | 2025 | |
| Glaxosmithkline, LLC. | $142.46 | 2021 | |
| Biotronik INC. | $90.26 | 2019-2025 | Biomonitor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $48.39 | 2025 | |
| Philips North America LLC | $37.49 | 2024 | (5044) Mcot |
| Edwards Lifesciences Corporation | $33.67 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Infobionic, INC | $23.17 | 2022 | |
| Genzyme Corporation | $21.48 | 2019 | |
| Irhythm Technologies, INC. | $21.02 | 2022 | |
| Lilly USA, LLC | $20.34 | 2025 | Mounjaro |
| Alnylam Pharmaceuticals INC. | $15.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulysses Walls listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.